Press release
Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition
LEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from its hematology program at the 65th American Society of Hematology (“ASH”) Annual Meeting and Exposition to be held in person and virtually from December 9 through 12, 2023. Keros will be presenting additional results from its two ongoing Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome (“MDS”) and one in patients with myelofibrosis. The following abstracts were posted to the ASH website on November 2, 2023, 9:00 a.m. Eastern time. Clinical Presentations “Durable Clinical Benefit with KER-050 treatment: Findings From an Ongoing Phase 2 Study in Participants with Lower-Risk MDS” Publication Number: 196Session Name: 637. MDS Clinical and Epidemiological: Treatment Options and Decision making in Low Risk MDSDate: Saturday, December 9, 2023Presentation Time: 2:00 p.m. – 4:00 p.m. Pacific time “Modulation of TGF-β Superfamily Signaling By KER-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia” Publication Number: 3185Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster IIDate: Sunday, December 10, 2023Presentation Time: 6:00 p.m. – 8:00 p.m. Pacific time “KER-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche” Publication Number: 1089Session Name: 102. Iron Homeostasis and BiologyDate: Saturday, December 9, 2023Presentation Time: 6:00 p.m. – 8:00 p.m. Pacific time Preclinical Presentations “RKER-050, A Modified Activin Receptor Type IIA Ligand Trap, Promoted Erythropoiesis in a Murine Model of Myelofibrosis” Publication Number: 4524Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster IIIDate: Monday, December 11, 2023Presentation Time: 6:00 p.m. – 8:00 p.m. Pacific time “RKE...